Display options
Cite
Marinescu CI, Leyes M, Ribas MA, et al. Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis. AIDS Res Treat. 2015;2015:106954doi: 10.1155/2015/106954.
Marinescu, C. I., Leyes, M., Ribas, M. A., Peñaranda, M., Murillas, J., Campins, A. A., Martin-Pena, L., Barcelo, B., Barceló-Campomar, C., Grases, F., Frontera, G., & Riera Jaume, M. (2015). Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis. AIDS research and treatment, 2015106954. https://doi.org/10.1155/2015/106954
Marinescu, C I, et al. "Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis." AIDS research and treatment vol. 2015 (2015): 106954. doi: https://doi.org/10.1155/2015/106954
Marinescu CI, Leyes M, Ribas MA, Peñaranda M, Murillas J, Campins AA, Martin-Pena L, Barcelo B, Barceló-Campomar C, Grases F, Frontera G, Riera Jaume M. Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis. AIDS Res Treat. 2015;2015:106954. doi: 10.1155/2015/106954. Epub 2015 May 07. PMID: 26064679; PMCID: PMC4439502.
Copy Download .nbib Format: NLM
Share it on

AIDS Res Treat. 2015;2015:106954. doi: 10.1155/2015/106954. Epub 2015 May 07.

Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis.

AIDS research and treatment

C I Marinescu, M Leyes, M A Ribas, M Peñaranda, J Murillas, A A Campins, L Martin-Pena, B Barcelo, C Barceló-Campomar, F Grases, G Frontera, Melchor Riera Jaume

Affiliations

  1. Infectious Disease Service, Son Espases Hospital, Carretera de Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain ; Multidisciplinary Group for Infectious Disease Service, Institute of Health Sciences Research, IdISPa, Health Research Foundation Ramón Llull (FISIB), Son Espases Hospital, Carretera de Valldemossa 79, Building "S", 1st Floor, Palma de Mallorca, 07010 Illes Balears, Spain.
  2. Clinical Analysis Service, Son Espases Hospital, Carretera de Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain.
  3. Pharmacy Service, Son Espases Hospital, Carretera de Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain.
  4. Laboratory of Renal Lithiasis Research (IUNICS-IDISPa), Universitat de les Illes Balears, Carretera de Valldemossa, km 7.5, Palma de Mallorca, 07010 Illes Balears, Spain.
  5. Clinical Trials Unit, Son Espases Hospital, Carretera Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain.

PMID: 26064679 PMCID: PMC4439502 DOI: 10.1155/2015/106954

Abstract

The main aim of this study is to describe the relationship between serum levels of atazanavir, renal toxicity, and lithiasis. This is a prospective observational study of patients being treated with atazanavir (ATV) at Son Espases Teaching Hospital, Palma de Mallorca, between 2011 and 2013. The study includes 98 patients. Sixteen were found to have a history of urolithiasis. During a median monitoring period of 23 months, nine patients suffered renal colic, in three of whom ATV crystals were evidenced in urine. Cumulative incidence of renal colic was 9.2 per 100 patients. The variables related to having renal colic were the presence of alkaline urine pH and lower basal creatinine clearance. The mean serum level of ATV was slightly higher in patients with renal colic-1,303 μg/L versus 1,161 μg/L-but did not reach statistical significance. Neither were any significant differences detected by analysing the levels according to the timetable for ATV dosage. Cumulative incidence of renal colic was high in patients being treated with ATV, in 33% of whom the presence of ATV crystals was evidenced in urine. We were unable to demonstrate a relationship between ATV serum levels and renal colic or progression towards renal failure.

References

  1. J Antimicrob Chemother. 2013 Jan;68(1):200-5 - PubMed
  2. Lancet. 2006 Jan 28;367(9507):333-44 - PubMed
  3. AIDS. 2012 Sep 24;26(15):1907-15 - PubMed
  4. Clin Ther. 2004 Dec;26(12):2045-55 - PubMed
  5. N Engl J Med. 2004 Feb 12;350(7):684-93 - PubMed
  6. J Antimicrob Chemother. 2013 Aug;68(8):1850-6 - PubMed
  7. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9 - PubMed
  8. J Infect. 2011 Apr;62(4):319-21 - PubMed
  9. Clin Infect Dis. 2012 Nov;55(9):1262-9 - PubMed
  10. AIDS. 2011 Aug 24;25(13):1671-3 - PubMed
  11. Kidney Int. 2011 Aug;80(3):302-9 - PubMed
  12. J Antimicrob Chemother. 2013 Jun;68(6):1364-72 - PubMed
  13. Urol Res. 2006 Apr;34(2):151-6 - PubMed
  14. Clin J Am Soc Nephrol. 2011 Jul;6(7):1700-7 - PubMed
  15. J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32 - PubMed
  16. PLoS One. 2013 Oct 10;8(10):e77268 - PubMed
  17. Clin Infect Dis. 2007 Oct 15;45(8):e105-8 - PubMed
  18. AIDS. 2010 Jul 17;24(11):1667-78 - PubMed
  19. J Infect Dis. 2008 Jun 15;197(12):1685-94 - PubMed

Publication Types